Neurodegeneration and demyelination in multiple sclerosis

T Garton, SP Gadani, AJ Gill, PA Calabresi - Neuron, 2024‏ - cell.com
Progressive multiple sclerosis (PMS) is an immune-initiated neurodegenerative condition
that lacks effective therapies. Although peripheral immune infiltration is a hallmark of …

The complement system as a target in cancer immunotherapy

NS Merle, LT Roumenina - European Journal of Immunology, 2024‏ - Wiley Online Library
Malignant cells are part of a complex network within the tumor microenvironment, where
their interaction with host cells and soluble mediators, including complement components, is …

Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution

MK Yadav, P Sarma, J Maharana, M Ganguly… - Nature …, 2024‏ - nature.com
The Hydroxycarboxylic acid receptor 2 (HCA2), also known as the niacin receptor or
GPR109A, is a prototypical GPCR that plays a central role in the inhibition of lipolytic and …

Molecular mechanism of distinct chemokine engagement and functional divergence of the human Duffy antigen receptor

S Saha, B Khanppnavar, J Maharana, H Kim… - Cell, 2024‏ - cell.com
The Duffy antigen receptor is a seven-transmembrane (7TM) protein expressed primarily at
the surface of red blood cells and displays strikingly promiscuous binding to multiple …

Complement 3a receptor 1 on macrophages and Kupffer cells is not required for the pathogenesis of metabolic dysfunction-associated steatotic liver disease

EA Homan, A Gilani, A Rubio-Navarro, MA Johnson… - Elife, 2025‏ - elifesciences.org
Together with obesity and type 2 diabetes, metabolic dysfunction-associated steatotic liver
disease (MASLD) is a growing global epidemic. Activation of the complement system and …

Functional profiling of the G protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism

P Rodriguez, LJ Laskowski, JP Pallais, HA Bock… - Journal of Biological …, 2024‏ - jbc.org
G protein-coupled receptors (GPCRs) are leading druggable targets for several medicines,
but many GPCRs are still untapped for their therapeutic potential due to poor understanding …

Molecular basis of promiscuous chemokine binding and structural mimicry at the CXC chemokine receptor, CXCR2

S Saha, FK Sano, S Sharma, M Ganguly, S Mishra… - Molecular Cell, 2025‏ - cell.com
Selectivity of natural agonists for their cognate receptors is a hallmark of G-protein-coupled
receptors (GPCRs); however, this selectivity often breaks down at the chemokine receptors …

Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease

M Gedam, H Zheng - European Journal of Immunology, 2024‏ - Wiley Online Library
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most
common cause of dementia among the elderly population. Despite its widespread …

Biased signaling in GPCRs: Structural insights and implications for drug development

Y Ma, B Patterson, L Zhu - Pharmacology & Therapeutics, 2024‏ - Elsevier
G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors in
humans, playing a crucial role in regulating diverse cellular processes and serving as …

The role and treatment potential of the complement pathway in chronic pain

M Vygonskaya, Y Wu, TJ Price, Z Chen, MT Smith… - The Journal of …, 2024‏ - Elsevier
The role of the complement system in pain syndromes has garnered attention on the back of
preclinical and clinical evidence supporting its potential as a target for new analgesic …